Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Lymphoma, Follicular 4Glioma 4Brain Neoplasms 4Rhabdoid Tumor 3Pinealoma 3Neuroectodermal Tumors, Primitive 3Neoplasms, Germ Cell and Embryonal 3Multiple Myeloma 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Ependymoma 3Choroid Plexus Carcinoma 3Central Nervous System Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, B-Cell, Marginal Zone 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Peripheral Blood Stem Cell Transplantation 24Whole-Body Irradiation 18Etoposide 18Doxorubicin 17Vincristine 16Mycophenolic Acid 16Cyclosporine 16Prednisone 15Tacrolimus 12Busulfan 12Bortezomib 12Methotrexate 11Antilymphocyte Serum 11Rituximab 10Melphalan 10Gemcitabine 9Carboplatin 9Lenalidomide 8Filgrastim 8Vorinostat 7Radiotherapy 7Everolimus 7Alemtuzumab 6romidepsin 5Methylprednisolone 5Ifosfamide 5Flow Cytometry 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoblastic Lymphadenopathy × Automobiles × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡